Lyell Immunopharma, Inc. (LYEL) — Capital Expenditures
| Fiscal Year | Capital Expenditures | Change YoY |
|---|---|---|
| 2025 | $780.0K | +68.1% |
| 2024 | $464.0K | -82.7% |
| 2023 | $2.69M | -88.9% |
| 2022 | $24.28M | -62.9% |
| 2021 | $65.50M | +27.2% |
| 2020 | $51.48M | +220.8% |
| 2019 | $16.05M | — |
| Fiscal Year | Capital Expenditures | Change YoY |
|---|---|---|
| 2025 | $780.0K | +68.1% |
| 2024 | $464.0K | -82.7% |
| 2023 | $2.69M | -88.9% |
| 2022 | $24.28M | -62.9% |
| 2021 | $65.50M | +27.2% |
| 2020 | $51.48M | +220.8% |
| 2019 | $16.05M | — |